Preclinical · PMID 41179234
ACTH 4-10 (Semax) Regulating the Inflammatory Cascade in Spinal Cord Injury — VialBase Research
Semax showed neuroprotective and anti-inflammatory properties in SCI
Last updated · 2025 · Various · F1000Research
Key findings
- Semax showed neuroprotective and anti-inflammatory properties in SCI
- Regulated inflammatory cascade by modulating cytokine balance
- Upregulated anti-inflammatory cytokines (IL-4, IL-13)
- Downregulated pro-inflammatory mediators (IL-1beta, TNF-alpha, MCP-1)
- No serious complications reported (consistent with clinical use for brain ischemia)
Semax Anti-Inflammatory Effects in Spinal Cord Injury (PMID: 41179234)
Study Design
- Preclinical SCI model
- Analyzed Semax (ACTH 4-10Pro8-Gly9-Pro10) effects on inflammatory cascade
- Measured anti-inflammatory and pro-inflammatory cytokine levels
Key Results
- Semax modulated the inflammatory cascade post-SCI
- Upregulated: IL-4, IL-13 (anti-inflammatory)
- Downregulated: IL-1beta, TNF-alpha, MCP-1 (pro-inflammatory)
- Consistent with known safety profile from brain ischemia clinical use
Relevance
Extends Semax applications beyond cognitive enhancement to neurotrauma. The anti-inflammatory mechanism parallels its neuroprotective action in stroke, suggesting a general CNS anti-inflammatory profile.
See Also
- Parent compound: Semax